View Item 

Show simple item record

Hydroxyurea use among children with sickle cell anemia
dc.contributor.authorReeves, Sarah L.
dc.contributor.authorJary, Hannah K.
dc.contributor.authorGondhi, Jennifer P.
dc.contributor.authorRaphael, Jean L.
dc.contributor.authorLisabeth, Lynda D.
dc.contributor.authorDombkowski, Kevin J.
dc.date.accessioned2019-05-31T18:26:13Z
dc.date.availableWITHHELD_14_MONTHS
dc.date.available2019-05-31T18:26:13Z
dc.date.issued2019-06
dc.identifier.citationReeves, Sarah L.; Jary, Hannah K.; Gondhi, Jennifer P.; Raphael, Jean L.; Lisabeth, Lynda D.; Dombkowski, Kevin J. (2019). "Hydroxyurea use among children with sickle cell anemia." Pediatric Blood & Cancer 66(6): n/a-n/a.
dc.identifier.issn1545-5009
dc.identifier.issn1545-5017
dc.identifier.urihttps://hdl.handle.net/2027.42/149259
dc.description.abstractThis study describes hydroxyurea use among children ages 1 to 17 with sickle cell anemia (SCA) enrolled in at least one year of Medicaid in six states from 2005 to 2012. Administrative claims were used to summarize the number of days’ supply of hydroxyurea dispensed by state and year. A total of 7963 children with SCA contributed 22 424 person‐years. Among person‐years with greater than 30 days of hydroxyurea, only 18% received at least 300 days of hydroxyurea, which varied by state. Following updated recommendations for all children with SCA to be offered hydroxyurea, strategies to increase hydroxyurea adherence among this population are needed.
dc.publisherWiley Periodicals, Inc.
dc.subject.otherhydroxyurea
dc.subject.otheradministrative claims
dc.subject.otherMedicaid
dc.subject.othersickle cell anemia
dc.titleHydroxyurea use among children with sickle cell anemia
dc.typeArticle
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelPediatrics
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/149259/1/pbc27721_am.pdf
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/149259/2/pbc27721.pdf
dc.identifier.doi10.1002/pbc.27721
dc.identifier.sourcePediatric Blood & Cancer
dc.identifier.citedreferenceThornburg CD, Calatroni A, Telen M, Kemper AR. Adherence to hydroxyurea therapy in children with sickle cell anemia. J Pediatr. 2010; 156 ( 3 ): 415 ‐ 419.
dc.identifier.citedreferenceCenters for Disease Control and Prevention. Sickle cell disease (SCD): data and statistics. 2016; https://www.cdc.gov/ncbddd/sicklecell/data.html. Accessed September 1, 2017.
dc.identifier.citedreferenceNational Heart Lung and Blood Institute. Sickle cell disease. 2017; https://www.nhlbi.nih.gov/health/health-topics/topics/sca. Accessed February 22, 2018.
dc.identifier.citedreferenceNational Heart Lung, and Blood Institute. The management of sickle cell disease. 2002; https://www.nhlbi.nih.gov/files/docs/guidelines/sc_mngt.pdf. Accessed February 22, 2019.
dc.identifier.citedreferenceJerrell JM, Tripathi A, McIntyre RS. Prevalence and treatment of depression in children and adolescents with sickle cell disease: a retrospective cohort study. Prim Care Companion CNS Disord. 2011; 13 ( 2 ). pii: PCC.10m01063.
dc.identifier.citedreferenceCacciotti C, Vaiselbuh S, Romanos‐Sirakis E. Pain Management for sickle cell disease in the pediatric emergency department: medications and hospitalization trends. Clin Pediatr (Phila). 2017; 56 ( 12 ): 1109 ‐ 1114.
dc.identifier.citedreferenceBou‐Maroun LM, Meta F, Hanba CJ, Campbell AD, Yanik GA. An analysis of inpatient pediatric sickle cell disease: incidence, costs, and outcomes. Pediatr Blood Cancer. 2018; 65 ( 1 ): e26758.
dc.identifier.citedreferenceNational Heart Lung and Blood Institute Evidenced‐Based Management of Sickle Cell Disease: Expert Panel Report. 2014; https://catalog.nhlbi.nih.gov/sites/default/files/publicationfiles/56-364NFULL.pdf. Accessed April 5, 2018.
dc.identifier.citedreferenceBrandow AM, Panepinto JA. Monitoring toxicity, impact, and adherence of hydroxyurea in children with sickle cell disease. Am J Hematol. 2011; 86 ( 9 ): 804 ‐ 806.
dc.identifier.citedreferenceMcGann PT, Ware RE. Hydroxyurea for sickle cell anemia: what have we learned and what questions still remain? Curr Opin Hematol. 2011; 18 ( 3 ): 158 ‐ 165.
dc.identifier.citedreferenceThornburg CD, Files BA, Luo Z, et al. Impact of hydroxyurea on clinical events in the BABY HUG trial. Blood. 2012; 120 ( 22 ): 4304 ‐ 4310.
dc.identifier.citedreferenceCandrilli SD, O’Brien SH, Ware RE, Nahata MC, Seiber EE, Balkrishnan R. Hydroxyurea adherence and associated outcomes among Medicaid enrollees with sickle cell disease. Am J Hematol. 2011; 86 ( 3 ): 273 ‐ 277.
dc.identifier.citedreferenceWalsh KE, Cutrona SL, Kavanagh PL, et al. Medication adherence among pediatric patients with sickle cell disease: a systematic review. Pediatrics. 2014; 134 ( 6 ): 1175 ‐ 1183.
dc.identifier.citedreferenceBadawy SM, Thompson AA, Penedo FJ, Lai JS, Rychlik K, Liem RI. Barriers to hydroxyurea adherence and health‐related quality of life in adolescents and young adults with sickle cell disease. Eur J Haematol. 2017; 98 ( 6 ): 608 ‐ 614.
dc.identifier.citedreferenceReeves SL, Jary HK, Gondhi JP, Kleyn M, Wagner AL, Dombkowski KJ. Pneumococcal vaccination coverage among children with sickle cell anemia, sickle cell trait, and normal hemoglobin. Pediatr Blood Cancer. 2018: e27282.
dc.identifier.citedreferenceReeves SL, Madden B, Shevrin CA, McCormick J, Freed GL, Dombkowski KJ. Antibiotic Prophylaxis Among Children with Sickle Cell Anemia. 2017; https://www.qualityforum.org/QPS/3166. Accessed January 9, 2019.
dc.identifier.citedreferenceNational Institutes of Health. RxNorm. 2018; https://www.nlm.nih.gov/research/umls/rxnorm/. Accessed May 22, 2018.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
pbc27721_am.pdf
Size:
468.3KB
Format:
PDF
View/Open
Name:
pbc27721.pdf
Size:
286.1KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.